Clinical trial
A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis
NCT02200718 is registered in ClinicalTrials.gov with Immune Response BioPharma, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis
- Lead sponsor
- Immune Response BioPharma, Inc.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- December 31, 2020
- Completion date
- November 9, 2024
- Enrollment
- 12 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.